Prix FOB
Obtenir le dernier prix|
- Minimum Order
Pays:
China
N ° de modèle:
-
Prix FOB:
Localité:
-
Prix de commande minimale:
-
Commande minimale:
-
Packaging Detail:
-
Heure de livraison:
-
Capacité de Fournir:
-
Payment Type:
-
Groupe de produits :
-
Personne àcontacter Dong
Road Lingong, Linyi, Shandong
Arena Pharmaceuticals has developed lorcaserin (Lorqess; Belviq; APD***6), the lead from a series of orally active, small-molecule *-HT 2c agonists. Lorcaserin is indicated in the US where it would be marketed by licensee Eisai, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of *0 kg/m2 or greater (obese) or *7 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia and type 2 diabetes)
| Pays: | China |
| N ° de modèle: | - |
| Prix FOB: | Obtenir le dernier prix |
| Localité: | - |
| Prix de commande minimale: | - |
| Commande minimale: | - |
| Packaging Detail: | - |
| Heure de livraison: | - |
| Capacité de Fournir: | - |
| Payment Type: | - |
| Groupe de produits : | - |
